# A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

> clinical trial · VERIFIED · 2026-08-24

Status: RECRUITING · Sponsor: BeOne Medicines · Condition: Chronic Lymphocytic Leukemia

- Company: BeOne Medicines
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06943872

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.